BofA raised the firm’s price target on Teladoc (TDOC) to $9 from $8.50 and keeps a Neutral rating on the shares after the company announced a CFO transition, reaffirmed its 2025 revenue and adjusted EBITDA outlook and provided preliminary Q3 results. The firm continues to view Teladoc as a differentiated asset given its broad scale and optionality from recent acquisitions, but remains cautious on the near-term outlook, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Mixed Signals: Neutral Rating Amid Growth in Chronic Care and CFO Departure Uncertainty
- Teladoc’s Transitional Phase: Hold Rating Amid Financial Stability and Strategic Shifts
- Teladoc backs FY25 EPS view ($1.35)-($1.00), consensus ($1.21)
- Teladoc reports preliminary Q3 revenue $626.4M, consensus $626.07M
- Teladoc CFO Mala Murthy to Resign in November